EssilorLuxottica has announced the acquisition of Ikerian AG, the health technology company operating under the RetinAI brand. The move expands the company's med-tech capabilities, especially in artificial intelligence (AI) and data-driven eye care, according to a press release.

RetinAI specializes in AI and data management for ophthalmology and optometry. Its flagship platform, RetinAI Discovery is both FDA 510(k) cleared and CE-marked, and offers machine learning–based tools that support diagnosis and disease monitoring for age-related macular degeneration, glaucoma, and diabetic retinopathy, according to a press release.

Specifically, the software enables clinicians to collect, process, and grade large-scale retinal image datasets. RetinAI Discovery is also used by pharmaceutical companies and research institutions to analyze real-world evidence and accelerate clinical studies and drug development.

According to the press release, the AI analytics will help EssilorLuxottica gain insights from clinical data and enable fast and accurate diagnoses, as well as disease monitoring. OM